Search research articles
Contact Us
Filters
Showing results (411-420 of 510) with videos related to
Page
of 51
Sort By:
The American Journal of Pathology
|
May 14, 2013
Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis
Emily R Gilbert, Jonathan M Eby, Adam M Hammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases
Marcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Future Oncology (London, England)
|
November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer
Jeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 11, 2023
The association between education and fear of recurrence among breast cancer patients in follow-up - and the mediating effect of self-efficacy
Cecilie Larsen, Kirstine S Kirchhoff, Lena Saltbæk, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
David S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Nature
|
June 17, 2021
Correlated charge noise and relaxation errors in superconducting qubits
C D Wilen, S Abdullah, N A Kurinsky, et al.
Cardiovascular Research
|
September 7, 2000
Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure
J K Damås, H G Eiken, E Oie, et al.
Cancer Research
|
October 30, 2010
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
Takaaki Sasaki, Katsuhiro Okuda, Wei Zheng, et al.
Science Translational Medicine
|
February 4, 2026
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models
Hai-Cheng Huang, Qing Deng, Lei Guo, et al.
European Journal of Immunology
|
November 19, 2014
TL1A regulates TCRγδ+ intraepithelial lymphocytes and gut microbial composition
Peter Tougaard, S Skov, A E Pedersen, et al.
Page
of 51
Search research articles
Search
Showing results (411-420 of 510) with videos related to
Sort By:
Page
of 51
The American Journal of Pathology
|
May 14, 2013
Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis
Emily R Gilbert, Jonathan M Eby, Adam M Hammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases
Marcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Future Oncology (London, England)
|
November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer
Jeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 11, 2023
The association between education and fear of recurrence among breast cancer patients in follow-up - and the mediating effect of self-efficacy
Cecilie Larsen, Kirstine S Kirchhoff, Lena Saltbæk, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
David S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Nature
|
June 17, 2021
Correlated charge noise and relaxation errors in superconducting qubits
C D Wilen, S Abdullah, N A Kurinsky, et al.
Cardiovascular Research
|
September 7, 2000
Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure
J K Damås, H G Eiken, E Oie, et al.
Cancer Research
|
October 30, 2010
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
Takaaki Sasaki, Katsuhiro Okuda, Wei Zheng, et al.
Science Translational Medicine
|
February 4, 2026
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models
Hai-Cheng Huang, Qing Deng, Lei Guo, et al.
European Journal of Immunology
|
November 19, 2014
TL1A regulates TCRγδ+ intraepithelial lymphocytes and gut microbial composition
Peter Tougaard, S Skov, A E Pedersen, et al.
Page
of 51